{
    "info": {
        "nct_id": "NCT06397573",
        "official_title": "Phase 1 Trial of Ablative Stereotactic MR-Guided Adaptive Reirradiation for Abdominal and Pelvic Tumors",
        "inclusion_criteria": "* A primary or metastatic lesion in the abdomen or pelvis for which reirradiation will be delivered. There is no maximum lesion size.\n* Single course of prior radiation therapy with prescribed equivalent dose in 2 Gy fractions (EDQ210) of at least 40 Gy.\n* 50% isodose line of the prior radiation therapy course is expected to overlap at minimum the 50% isodose line of the radiation therapy delivered in this study.\n* At least 6 months from completion of prior radiation therapy to initiation of study therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Life expectancy at least 6 months.\n* Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Abstinence is acceptable if it is the participant's preferred method. Should a participant become pregnant or suspect pregnancy while participating in this study, the treating physician must be informed immediately.\n* Concurrent hormonal therapy or immunotherapy such as immune checkpoint inhibitor is allowed\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Contraindication to having an MRI scan.\n* Lesion that would receive study therapy arises from or invades a gastrointestinal (GI) luminal organ (a lesion abutting but not invading a GI luminal organ is permitted)\n* Lesion that would receive study therapy is not located in the abdomen or pelvis.\n* > 1 course of overlapping radiation therapy delivered to the abdomen or pelvis.\n* < 70% of the gross tumor volume (GTV) receives at least the 95% of the prescribed dose on the original plan using the simulation day anatomy.\n* More than 1 lesion in the abdomen or pelvis that requires reirradiation.\n* History of inflammatory bowel disease.\n* Unable to acquire DICOM radiation therapy treatment plan from the prior radiation therapy.\n* Unresolved grade 2+ toxicity (Common Terminology Criteria for Adverse Events version 5.0) from previous anti-cancer therapy.\n* Any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of participant safety or study results.\n* Individuals who are pregnant.\n* Chemotherapy given within 1 week prior to or following reirradiation.\n* Vascular endothelial growth factor (VEGF) inhibitor given within 8 weeks prior to or following reirradiation",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 50% isodose line of the prior radiation therapy course is expected to overlap at minimum the 50% isodose line of the radiation therapy delivered in this study.",
            "criterions": [
                {
                    "exact_snippets": "50% isodose line of the prior radiation therapy course is expected to overlap at minimum the 50% isodose line of the radiation therapy delivered in this study",
                    "criterion": "isodose line overlap between prior and current radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "overlap",
                            "expected_value": "at minimum the 50% isodose line of the prior course overlaps the 50% isodose line of the current course"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy at least 6 months.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy at least 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Abstinence is acceptable if it is the participant's preferred method. Should a participant become pregnant or suspect pregnancy while participating in this study, the treating physician must be informed immediately.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "hormonal",
                                "barrier"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to study entry and for the duration of study participation"
                        }
                    ]
                },
                {
                    "exact_snippets": "Abstinence is acceptable if it is the participant's preferred method.",
                    "criterion": "abstinence as contraception",
                    "requirements": [
                        {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "if it is the participant's preferred method"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent hormonal therapy or immunotherapy such as immune checkpoint inhibitor is allowed",
            "criterions": [
                {
                    "exact_snippets": "Concurrent hormonal therapy ... is allowed",
                    "criterion": "concurrent hormonal therapy",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concurrent ... immunotherapy such as immune checkpoint inhibitor is allowed",
                    "criterion": "concurrent immunotherapy (such as immune checkpoint inhibitor)",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Single course of prior radiation therapy with prescribed equivalent dose in 2 Gy fractions (EDQ210) of at least 40 Gy.",
            "criterions": [
                {
                    "exact_snippets": "Single course of prior radiation therapy",
                    "criterion": "prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of courses",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "course"
                            }
                        },
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prescribed equivalent dose in 2 Gy fractions (EDQ210) of at least 40 Gy",
                    "criterion": "prescribed equivalent dose in 2 Gy fractions (EDQ210)",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "Gy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A primary or metastatic lesion in the abdomen or pelvis for which reirradiation will be delivered. There is no maximum lesion size.",
            "criterions": [
                {
                    "exact_snippets": "A primary or metastatic lesion in the abdomen or pelvis",
                    "criterion": "lesion location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "abdomen",
                                "pelvis"
                            ]
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "primary",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for which reirradiation will be delivered",
                    "criterion": "planned reirradiation",
                    "requirements": [
                        {
                            "requirement_type": "planned treatment",
                            "expected_value": "reirradiation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 6 months from completion of prior radiation therapy to initiation of study therapy.",
            "criterions": [
                {
                    "exact_snippets": "At least 6 months from completion of prior radiation therapy to initiation of study therapy.",
                    "criterion": "time since completion of prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Individuals who are pregnant.",
            "criterions": [
                {
                    "exact_snippets": "Individuals who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lesion that would receive study therapy is not located in the abdomen or pelvis.",
            "criterions": [
                {
                    "exact_snippets": "Lesion that would receive study therapy is not located in the abdomen or pelvis",
                    "criterion": "location of lesion that would receive study therapy",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": {
                                "operator": "!=",
                                "value": 0,
                                "unit": "abdomen or pelvis"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of inflammatory bowel disease.",
            "criterions": [
                {
                    "exact_snippets": "History of inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* More than 1 lesion in the abdomen or pelvis that requires reirradiation.",
            "criterions": [
                {
                    "exact_snippets": "More than 1 lesion in the abdomen or pelvis",
                    "criterion": "number of lesions in the abdomen or pelvis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lesions"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "lesion ... that requires reirradiation",
                    "criterion": "lesion reirradiation requirement",
                    "requirements": [
                        {
                            "requirement_type": "reirradiation requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* > 1 course of overlapping radiation therapy delivered to the abdomen or pelvis.",
            "criterions": [
                {
                    "exact_snippets": "> 1 course of overlapping radiation therapy delivered to the abdomen or pelvis",
                    "criterion": "overlapping radiation therapy to the abdomen or pelvis",
                    "requirements": [
                        {
                            "requirement_type": "number of courses",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "courses"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vascular endothelial growth factor (VEGF) inhibitor given within 8 weeks prior to or following reirradiation",
            "criterions": [
                {
                    "exact_snippets": "Vascular endothelial growth factor (VEGF) inhibitor given within 8 weeks prior to or following reirradiation",
                    "criterion": "VEGF inhibitor administration",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to reirradiation",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy given within 1 week prior to or following reirradiation.",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy given within 1 week prior to or following reirradiation.",
                    "criterion": "chemotherapy administration timing",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to reirradiation",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": -7,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Contraindication to having an MRI scan.",
            "criterions": []
        },
        {
            "line": "* Unresolved grade 2+ toxicity (Common Terminology Criteria for Adverse Events version 5.0) from previous anti-cancer therapy.",
            "criterions": []
        },
        {
            "line": "* Lesion that would receive study therapy arises from or invades a gastrointestinal (GI) luminal organ (a lesion abutting but not invading a GI luminal organ is permitted)",
            "criterions": []
        },
        {
            "line": "* Any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of participant safety or study results.",
            "criterions": []
        },
        {
            "line": "* < 70% of the gross tumor volume (GTV) receives at least the 95% of the prescribed dose on the original plan using the simulation day anatomy.",
            "criterions": []
        },
        {
            "line": "* Unable to acquire DICOM radiation therapy treatment plan from the prior radiation therapy.",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}